In phase 1/2 or phase 2 studies, patients with soft tissue sarcoma and ovarian cancer have been treated with trabectedin and anti-PD-1, anti-PD-L1 or anti-CTLA-4 (nivolumab, durvalumab, ipilimumab), while patients with small cell lung cancer (SCLC) have been treated with lurbinectedin and anti-PD-L1 or anti-CTLA-4 (atezolizumab, ipilimumab). Here, CD274 is linked to soft tissue sarcoma.